

Daniela Maria Cardinale

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4329482/publications.pdf>

Version: 2024-02-01

99
papers

12,759
citations

70961

41
h-index

42291

92
g-index

103
all docs

103
docs citations

103
times ranked

9117
citing authors

#	ARTICLE	IF	CITATIONS
1	Early Detection of Anthracycline Cardiotoxicity and Improvement With Heart Failure Therapy. <i>Circulation</i> , 2015, 131, 1981-1988.	1.6	1,179
2	Expert Consensus for Multimodality Imaging Evaluation of Adult Patients during and after Cancer Therapy: A Report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. <i>Journal of the American Society of Echocardiography</i> , 2014, 27, 911-939.	1.2	1,051
3	Anthracycline-Induced Cardiomyopathy. <i>Journal of the American College of Cardiology</i> , 2010, 55, 213-220.	1.2	949
4	2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. <i>European Journal of Heart Failure</i> , 2017, 19, 9-42.	2.9	920
5	Prevention of High-Dose Chemotherapy-Induced Cardiotoxicity in High-Risk Patients by Angiotensin-Converting Enzyme Inhibition. <i>Circulation</i> , 2006, 114, 2474-2481.	1.6	875
6	Prognostic Value of Troponin I in Cardiac Risk Stratification of Cancer Patients Undergoing High-Dose Chemotherapy. <i>Circulation</i> , 2004, 109, 2749-2754.	1.6	797
7	Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. <i>European Heart Journal Cardiovascular Imaging</i> , 2014, 15, 1063-1093.	0.5	739
8	Trastuzumab-Induced Cardiotoxicity: Clinical and Prognostic Implications of Troponin I Evaluation. <i>Journal of Clinical Oncology</i> , 2010, 28, 3910-3916.	0.8	554
9	Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management. <i>Ca-A Cancer Journal for Clinicians</i> , 2016, 66, 309-325.	157.7	485
10	Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. <i>Journal of the American College of Cardiology</i> , 2000, 36, 517-522.	1.2	463
11	Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society. <i>European Journal of Heart Failure</i> , 2020,	2.9	364
12	The Prognostic Value of Pre-Operative and Post-Operative B-Type Natriuretic Peptides in Patients Undergoing Noncardiac Surgery. <i>Journal of the American College of Cardiology</i> , 2014, 63, 170-180.	1.2	270
13	Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy. <i>Annals of Oncology</i> , 2002, 13, 710-715.	0.6	261
14	Cancer Therapy-Related Cardiac Dysfunction and Heart Failure. <i>Circulation: Heart Failure</i> , 2016, 9, e002661.	1.6	241
15	Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement. <i>European Heart Journal</i> , 2022, 43, 280-299.	1.0	213
16	Cardiotoxicity of Anthracyclines. <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 26.	1.1	212
17	N-Terminal Pro-B-Type Natriuretic Peptide after High-Dose Chemotherapy: A Marker Predictive of Cardiac Dysfunction?. <i>Clinical Chemistry</i> , 2005, 51, 1405-1410.	1.5	207
18	Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2020, 22, 1966-1983.	2.9	184

#	ARTICLE	IF	CITATIONS
19	Biochemical Markers for Prediction of Chemotherapy-Induced Cardiotoxicity. American Journal of Clinical Pathology, 2008, 130, 688-695.	0.4	170
20	Anthracycline-induced cardiotoxicity: A multicenter randomised trial comparing two strategies for guiding prevention with enalapril: The International CardioOncology Society-oneAtrial. European Journal of Cancer, 2018, 94, 126-137.	1.3	163
21	Classification, prevalence, and outcomes of anticancer therapy-induced cardiotoxicity: the CARDIOTOX registry. European Heart Journal, 2020, 41, 1720-1729.	1.0	154
22	Obesity As a Risk Factor for Anthracyclines and Trastuzumab Cardiotoxicity in Breast Cancer: A Systematic Review and Meta-Analysis. Journal of Clinical Oncology, 2016, 34, 3157-3165.	0.8	149
23	Role of Biomarkers in Chemotherapy-Induced Cardiotoxicity. Progress in Cardiovascular Diseases, 2010, 53, 121-129.	1.6	133
24	Cancer Therapy-Related Cardiac Dysfunction and Heart Failure. Circulation: Heart Failure, 2016, 9, e002843.	1.6	109
25	Minor Increases in Plasma Troponin I Predict Decreased Left Ventricular Ejection Fraction after High-Dose Chemotherapy. Clinical Chemistry, 2003, 49, 248-252.	1.5	105
26	Increased Perioperative N-Terminal Pro-B-Type Natriuretic Peptide Levels Predict Atrial Fibrillation After Thoracic Surgery for Lung Cancer. Circulation, 2007, 115, 1339-1344.	1.6	97
27	Strategies to Prevent and Treat Cardiovascular Risk in Cancer Patients. Seminars in Oncology, 2013, 40, 186-198.	0.8	87
28	Postoperative B-type Natriuretic Peptide for Prediction of Major Cardiac Events in Patients Undergoing Noncardiac Surgery. Anesthesiology, 2013, 119, 270-283.	1.3	87
29	Early reduction in left ventricular contractile reserve detected by dobutamine stress echo predicts high-dose chemotherapy-induced cardiac toxicity. International Journal of Cardiology, 2006, 111, 120-126.	0.8	85
30	Atrial fibrillation after operation for lung cancer: clinical and prognostic significance. Annals of Thoracic Surgery, 1999, 68, 1827-1831.	0.7	80
31	The Compelling Need for a Cardiology and Oncology Partnership and the Birth of the International CardioOncology Society. Progress in Cardiovascular Diseases, 2010, 53, 88-93.	1.6	77
32	Long-term Results of Intrapericardial Chemotherapeutic Treatment of Malignant Pericardial Effusions With Thiotepea. Chest, 2004, 126, 1412-1416.	0.4	67
33	Using biomarkers to predict and to prevent cardiotoxicity of cancer therapy. Expert Review of Molecular Diagnostics, 2017, 17, 245-256.	1.5	66
34	Cardiac Toxicity of Anticancer Agents. Current Cardiology Reports, 2013, 15, 362.	1.3	65
35	The cancer patient and cardiology. European Journal of Heart Failure, 2020, 22, 2290-2309.	2.9	62
36	Doxorubicin and Trastuzumab Regimen Induces Biventricular Failure in Mice. Journal of the American Society of Echocardiography, 2014, 27, 568-579.	1.2	61

#	ARTICLE	IF	CITATIONS
37	Curing Cancer, Saving the Heart: A Challenge That Cardiology Should Not Miss. <i>Current Cardiology Reports</i> , 2016, 18, 51.	1.3	56
38	Prevention of Atrial Fibrillation in High-risk Patients Undergoing Lung Cancer Surgery. <i>Annals of Surgery</i> , 2016, 264, 244-251.	2.1	55
39	Cardiac toxicity in cancer survivors. <i>Cancer</i> , 2013, 119, 2131-2142.	2.0	49
40	Major Adverse Cardiovascular Events Associated With Postoperative Atrial Fibrillation After Noncardiac Surgery. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2020, 13, e007437.	2.1	49
41	Oxidative stress and inflammation: determinants of anthracycline cardiotoxicity and possible therapeutic targets. <i>Heart Failure Reviews</i> , 2021, 26, 881-890.	1.7	43
42	Role of biomarkers in cardiology. <i>Clinical Chemistry and Laboratory Medicine</i> , 2011, 49, 1937-48.	1.4	42
43	Intrapericardial Treatment of Neoplastic Pericardial Effusions. <i>Herz</i> , 2000, 25, 787-793.	0.4	39
44	Acute kidney injury after lung cancer surgery. <i>Lung Cancer</i> , 2018, 123, 155-159.	0.9	35
45	Managing Cardiotoxicity of Chemotherapy. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2013, 15, 410-424.	0.4	33
46	Anticoagulation in patients with atrial fibrillation and active cancer: an international survey on patient management. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 611-621.	0.8	33
47	Acute coronary syndrome induced by oral capecitabine. <i>Canadian Journal of Cardiology</i> , 2006, 22, 251-253.	0.8	32
48	Prevention and treatment of cardiomyopathy and heart failure in patients receiving Cancer Chemotherapy. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2008, 10, 486-495.	0.4	32
49	Usefulness of excitable gap and pattern of resetting in atrial flutter for determining reentry circuit location. <i>American Journal of Cardiology</i> , 1991, 68, 492-497.	0.7	29
50	Cardio-Oncology care in the era of the coronavirus disease 2019 (COVID-19) pandemic: An International Cardio-Oncology Society (ICOS) statement. <i>Ca-A Cancer Journal for Clinicians</i> , 2020, 70, 480-504.	157.7	29
51	Using cardiac biomarkers and treating cardiotoxicity in cancer. <i>Future Cardiology</i> , 2013, 9, 105-118.	0.5	27
52	Cardiac Complications of Chemotherapy: Role of Biomarkers. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2014, 16, 313.	0.4	27
53	Circulating MicroRNAs as Potential Predictors of Anthracycline-Induced Troponin Elevation in Breast Cancer Patients: Diverging Effects of Doxorubicin and Epirubicin. <i>Journal of Clinical Medicine</i> , 2020, 9, 1418.	1.0	27
54	Role of Cardiac Biomarkers in Cancer Patients. <i>Cancers</i> , 2021, 13, 5426.	1.7	22

#	ARTICLE	IF	CITATIONS
55	Cardio-oncology: Gaps in Knowledge, Goals, Advances, and Educational Efforts. <i>Current Oncology Reports</i> , 2017, 19, 55.	1.8	18
56	Association of Breast Cancer Irradiation With Cardiac Toxic Effects. <i>JAMA Oncology</i> , 2021, 7, 924.	3.4	17
57	Chemotherapy-induced cardiotoxicity: importance of early detection. <i>Expert Review of Cardiovascular Therapy</i> , 2016, 14, 1297-1299.	0.6	16
58	Circulating biomarkers and cardiac function over 3 years after chemotherapy with anthracyclines: the ICOS trial. <i>ESC Heart Failure</i> , 2020, 7, 1452-1466.	1.4	16
59	Assessment of cardiotoxicity with cardiac biomarkers in cancer patients. <i>Herz</i> , 2011, 36, 325-332.	0.4	15
60	Diagnostic and Prognostic Utility of Circulating Cytochrome c in Acute Myocardial Infarction. <i>Circulation Research</i> , 2016, 119, 1339-1346.	2.0	15
61	Circulating Cytochrome c as Potential Biomarker of Impaired Reperfusion in ST-Segment Elevation Acute Myocardial Infarction. <i>American Journal of Cardiology</i> , 2010, 106, 1443-1449.	0.7	14
62	Characteristics, Management, and Outcomes of Acute Coronary Syndrome Patients with Cancer. <i>Journal of Clinical Medicine</i> , 2020, 9, 3642.	1.0	14
63	Troponin I and Cardiovascular Risk Stratification in Patients With Testicular Cancer. <i>Journal of Clinical Oncology</i> , 2006, 24, 3508-3508.	0.8	13
64	Prevention, Monitoring, and Management of Cardiac Dysfunction in Patients with Metastatic Breast Cancer. <i>Oncologist</i> , 2019, 24, e1034-e1043.	1.9	13
65	ecancermedalscience. <i>Ecancermedalscience</i> , 2014, 8, 433.	0.6	12
66	Atrial fibrillation after thoracic surgery for lung cancer: use of a single cut-off value of N-terminal pro-B type natriuretic peptide to identify patients at risk. <i>Biomarkers</i> , 2010, 15, 259-265.	0.9	12
67	TnI-Ultra assay measurements in cancer patients: Comparison with the conventional assay and clinical implication. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2014, 74, 385-391.	0.6	12
68	The breast cancer patient in the cardioncology unit. <i>Journal of Thoracic Disease</i> , 2018, 10, S4306-S4322.	0.6	12
69	Incidence, Management, Prevention and Outcome of Post-Operative Atrial Fibrillation in Thoracic Surgical Oncology. <i>Journal of Clinical Medicine</i> , 2020, 9, 37.	1.0	12
70	Cardiac dysfunction after cancer treatment. <i>Texas Heart Institute Journal</i> , 2011, 38, 248-52.	0.1	11
71	Prokineticin Receptor-1 Signaling Inhibits Dose- and Time-Dependent Anthracycline-Induced Cardiovascular Toxicity Via Myocardial and Vascular Protection. <i>JACC: CardioOncology</i> , 2019, 1, 84-102.	1.7	10
72	Detection and monitoring of cardiotoxicity by using biomarkers: Pros and cons. <i>Progress in Pediatric Cardiology</i> , 2015, 39, 77-84.	0.2	9

#	ARTICLE	IF	CITATIONS
73	Subclinical cardiac damage in cancer patients before chemotherapy. <i>Heart Failure Reviews</i> , 2022, 27, 1091-1104.	1.7	9
74	Atrial Fibrillation after Lung Cancer Surgery: Prediction, Prevention and Anticoagulation Management. <i>Cancers</i> , 2021, 13, 4012.	1.7	8
75	High-sensitivity cardiac troponin I and T methods for the early detection of myocardial injury in patients on chemotherapy. <i>Clinical Chemistry and Laboratory Medicine</i> , 2021, 59, 513-521.	1.4	8
76	Cardiotoxic effects and myocardial injury: the search for a more precise definition of drug cardiotoxicity. <i>Clinical Chemistry and Laboratory Medicine</i> , 2021, 59, 51-57.	1.4	8
77	How to identify anthracycline-induced cardiotoxicity early and reduce its clinical impact in everyday practice. <i>Kardiologia Polska</i> , 2021, 79, 114-122.	0.3	7
78	Preventive Cardio-Oncology: Cardiovascular Disease Prevention in Cancer Patients and Survivors. Current Treatment Options in Cardiovascular Medicine, 2021, 23, 1.	0.4	5
79	Ischaemic and bleeding risk in cancer patients undergoing PCI: another brick in the wall. <i>European Heart Journal</i> , 2021, 42, 1035-1037.	1.0	5
80	Managing cardiac risk factors in oncology clinical trials. <i>Texas Heart Institute Journal</i> , 2011, 38, 266-7.	0.1	5
81	Oncologic therapies associated with cardiac toxicities: how to minimize the risks. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 359-374.	1.1	4
82	Nonrandomized Comparison between Concomitant and Sequential Chemoradiotherapy with Anthracyclines in Breast Cancer. <i>Tumori</i> , 2015, 101, 64-71.	0.6	3
83	Response to Letters Regarding Article, "Early Detection of Anthracycline Cardiotoxicity and Improvement With Heart Failure Therapy". <i>Circulation</i> , 2016, 133, e363.	1.6	3
84	Treating Asymptomatic Chemotherapy-Induced Cardiac Dysfunction. <i>Journal of the American College of Cardiology</i> , 2011, 57, 1790.	1.2	2
85	Cardioncological Approach for Trastuzumab Therapy in Breast Cancer Patients With Cardiotoxicity: Impact on Adherence and Clinical Outcome. <i>Frontiers in Pharmacology</i> , 2020, 11, 1190.	1.6	2
86	In Vivo Murine Models of Cardiotoxicity Due to Anticancer Drugs: Challenges and Opportunities for Clinical Translation. <i>Journal of Cardiovascular Translational Research</i> , 2022, , 1.	1.1	2
87	Treatment and prevention of cardiotoxicity due to anticancer therapy. <i>Journal of Cardiovascular Echography</i> , 2011, 21, 92-100.	0.1	1
88	High-volume hydration for the prevention of acute kidney injury after cardiac surgery. <i>Journal of Thoracic Disease</i> , 2019, 11, S1135-S1138.	0.6	1
89	Acute kidney injury: a common prognostic condition for different pathogenetic triggers?. <i>Journal of Thoracic Disease</i> , 2019, 11, E112-E114.	0.6	1
90	Cancer Cardiotoxicity and Cardiac Biomarkers. <i>Biomarkers in Disease</i> , 2015, , 73-105.	0.0	1

#	ARTICLE	IF	CITATIONS
91	Response to Letter Regarding Article, "Prevention of High-Dose Chemotherapy-Induced Cardiotoxicity in High-Risk Patients by Angiotensin-Converting Enzyme Inhibition". Circulation, 2007, 115, .	1.6	0
92	Reply to S. Goel et al and P.A. Kavsak et al. Journal of Clinical Oncology, 2011, 29, e178-e179.	0.8	0
93	Reply to R. Steiner et al. Journal of Clinical Oncology, 2013, 31, 1380-1380.	0.8	0
94	Cancer Cardiotoxicity and Cardiac Biomarkers. , 2014, , 1-26.		0
95	Diagnostic Tests in Cardio-oncology. , 2016, , 313-343.		0
96	Heart Failure in Oncologic Patients. , 2016, , 511-533.		0
97	Using biomarkers and early prophylactic treatment to prevent cardiotoxicity in cancer patients on chemotherapy. SA Heart Journal, 2017, 9, .	0.0	0
98	Cardiotoxicity: Left Ventricular Dysfunction. , 2017, , 123-141.		0
99	Abstract 13232: Prokineticin as a Biomarker of Cardiotoxicity in Cancer Patients. Circulation, 2021, 144, .	1.6	0